Brain Cancer Trial, Recruiting NCT06136611 Sponsor: The Christie NHS Foundation Trust Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06136611
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 35 years of age
  • People of any sex (male or female)
  • People who have recently been diagnosed with glioblastoma (a type of brain tumour) based on a scan
  • People who are largely able to carry out daily activities with little to no limitation (as assessed by their medical team using a standard health scale)
  • People whose case has been reviewed by a specialist brain tumour team — including a brain surgeon, cancer specialist, radiologist, and pathologist — who agree that joining the study is safe and appropriate
  • People whose lead trial doctor has confirmed at the first clinic visit that taking part is safe, including that they do not have severe symptoms from pressure on the brain
  • People for whom the medical team plans to carry out surgical removal of the tumour followed by standard radiation treatment
  • People whose blood counts, clotting, and kidney function are at levels considered acceptable by their medical team for surgery and scan dye (contrast agent)
  • People who have the mental capacity to make decisions about their own treatment
  • People who are willing and able to give their informed consent to take part

For people being considered for the experimental treatment arm specifically:

  • People who are willing and able to shave their head continuously as required by the study
  • People who are willing and able to wear a specialised medical device (called Optune) for the required amount of time each day

Who may not be able to join:

  • People whose seizures are not currently under control
  • People for whom only a biopsy (a small tissue sample) is planned, rather than surgical removal of the tumour
  • People who have a suspected or confirmed other cancer, with the exception of certain cancers: non-melanoma skin cancer, a cancer that has been fully removed, or prostate cancer with a very low PSA level (0.1 ng/ml or below) within the past three years
  • People who are unable to have a contrast-enhanced MRI scan — for example, due to severe claustrophobia or an allergy to the scan dye (gadolinium)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0161 446 3000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Christie NHS Foundation Trust
Registry
ClinicalTrials.gov
Start date
19 December 2024
Est. completion
3 September 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

To determine the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Pre-Operative and Pre-Radiotherapy TTFields additional to the standard treatment of care (SoC) including adjuvant TTFields.; To determine the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Pre-Operative and Pre-Radiotherapy TTFields additional to the standard treatment of care (SoC) including adjuvant TTFields.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov